Tilray Brands - American Cannabis Update
Tilray Sees Cannabis Rescheduling as
Gateway to U.S. Medical Market
Dean Seal, Dow Jones Newswire Jan. 10, 2024 at 7:32 PM EST
Tilray Brands believes it can get into the medical marijuana
business
in the U.S. pretty quickly if the Biden administration reclassifies
cannabis as a Schedule 3 drug sometime this year,
CEO Irwin Simon tells WSJ.
As one of the largest medical cannabis businesses in both
Canada and Europe, Tilray has "the expertise in growth, the
research and the
know-how" to launch medical cannabis operations in the U.S. expeditiously, whether through a greenfield approach or by
acquiring an existing player in the States, Simon says.
The CEO says Tilray would target the big markets on both coasts,
including California and New York.